COMMUNIQUÉS West-GlobeNewswire
-
How Meaningful Work Supports Long-Term Sobriety
01/07/2026 -
Correction: Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares
01/07/2026 -
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
01/07/2026 -
Rentschler Biopharma appoints Dr. Torsten Woehr as Chief Executive Officer
01/07/2026 -
PolarityBio Announces Submission of its Biologics License Application for SkinTE® for the Treatment of Wagner Grade 1 Diabetic Foot Ulcers
01/07/2026 -
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform
01/07/2026 -
evermore and Brookshire Brothers Partner to Bring Health Benefit Access to Rural and Underserved Communities Across Texas and Louisiana
01/07/2026 -
Amoéba has received marketing authorization in France for its biofungicide AXPERA
01/07/2026 -
Applied Biologics Announces Expanded Strategic Focus on Surgical Applications of XWRAP®
01/07/2026 -
Human Appeal supports Syrian farmers through new wheat supply chain project
01/07/2026 -
Beta Bionics to Announce Second Quarter 2026 Financial Results on July 29, 2026
01/07/2026 -
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
01/07/2026 -
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
01/07/2026 -
Abivax annonce la fixation du prix de l’Offre au public largement sursouscrite de 800 M$ (702 M€) d’American Depositary Shares
01/07/2026 -
Evaxion to present new preclinical data for cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop
01/07/2026 -
Milestone Scientific Reports Preliminary 1H 2026 Revenue of ~$5.0M, +9% YoY; Q2 2026 Revenue of ~$2.8M, +21% YoY
01/07/2026 -
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
01/07/2026 -
SERB Pharmaceuticals Completes Acquisition of European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma
01/07/2026 -
Artelo Biosciences Announces New Data Supporting ART26.12 as a Potential First-in-Class Therapy for Chronic Pain associated with Spinal Cord Injury
01/07/2026
Pages